Stay updated with breaking news from These Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Merck today announced the launch of pivotal Phase 3 trials for four of its investigational drug candidates against hematological malignancies and solid tumors. These global studies involve: -...
LARKSPUR, Calif.--(BUSINESS WIRE)--Dec 18, 2023--
Operator: Hello and welcome to the Moleculin Biotech Fiscal Year 2022 Quarterly Update Conference Call and Webcast. A question-and-answer session will follow the formal presentation.
- Phase 2 data demonstrate that the addition of parsaclisib to ruxolitinib (Jakafi®) resulted in spleen volume reduction and improvement in symptom burden in patients with myelofibrosis (MF) - Initial results of a Phase 1/2 study evaluating the safety and tolerability of INCB00928, an ALK2 inhibitor, show INCB00928 improves anemia in patients with MF both as monotherapy and in combination with ruxolitinib - These studies are part of our LIMBER program evaluating ruxolitinib combinations and potential new targets for appropriate patients with myeloproliferative neoplasms (MPNs)
The Genshin Impact 3.3 release date, time, and 3.3 Banner and event schedule - featuring, Scaramouche, Faruzan, a new Archon Interlude quest, TCG, and events.